

ORION MANUFACTURING FACILITY UPDATE

Acrux (ASX: ACR) today provided an update on the progress of remedial action at Orion Corporation's manufacturing facility following smoke damage from a fire in the basement area. Acrux currently anticipates that production of Axiron at the facility will recommence during the week beginning 12 December 2011.

The temporary suspension of manufacturing has not impacted the supply of Axiron to patients in the United States market.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products marketed by licensees in the USA, two products approved in Europe, one product in registration in the USA and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.